{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:34:35Z","timestamp":1784374475075,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010564","name":"Deutsches Zentrum f\u00fcr Lungenforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Evidence for the efficiency of highly-effective triple-CFTR-modulatory therapy with elexacaftor\/tezacaftor\/ivacaftor (ETI), either demonstrated in clinical trials or by <jats:italic>in vitro<\/jats:italic> testing, is lacking for about 10% of people with cystic fibrosis (pwCF) with rare mutations. Comprehensive assessment of CFTR function can provide critical information on the impact of ETI on CFTR function gains for such rare mutations, lending argument of the prescription of ETI. The mutation c.165-2A&amp;gt;G is a rare acceptor splice mutation that has not yet been functionally characterized. We here describe the functional changes induced by ETI in two brothers who are compound heterozygous for the splice mutations c.273+1G&amp;gt;C and c.165-2A&amp;gt;G.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We assessed the effects of ETI on CFTR function by quantitative pilocarpine iontophoresis (QPIT), nasal potential difference measurements (nPD), intestinal current measurements (ICM), \u03b2-adrenergic sweat secretion tests (SST) and multiple breath washout (MBW) prior to and 4\u00a0months after the initiation of ETI.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Functional CFTR analysis prior to ETI showed no CFTR function in the respiratory and intestinal epithelia and in the sweat gland reabsorptive duct in either brother. In contrast, \u03b2-adrenergic stimulated, CFTR-mediated sweat secretion was detectable in the CF range. Under ETI, both brothers continued to exhibit high sweat chloride concentration in QPIT, evidence of low residual CFTR function in the respiratory epithelia, but normalized \u03b2-adrenergically stimulated production of primary sweat.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> Our results are the first to demonstrate that the c.165-2A&amp;gt;G\/c.273+1G&amp;gt;C mutation genotype permits mutant CFTR protein expression. We showed organ-specific differences in the expression of CFTR and consecutive responses to ETI of the c.165-2A&amp;gt;G\/c.273+1G&amp;gt;C CFTR mutants that are probably accomplished by non-canonical CFTR mRNA isoforms. This showcase tells us that the individual response of rare <jats:italic>CFTR<\/jats:italic> mutations to highly-effective CFTR modulation cannot be predicted from assays in standard cell cultures, but requires the personalized multi-organ assessment by CFTR biomarkers.<\/jats:p>","DOI":"10.3389\/fphar.2023.1153656","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T05:57:55Z","timestamp":1679896675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Differential effects of ELX\/TEZ\/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G&gt;A and c.165-2A&gt;G"],"prefix":"10.3389","volume":"14","author":[{"given":"Sophia T.","family":"Pallenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dopfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Minso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel M.","family":"Nietert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"T\u00fcmmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF02272843","article-title":"Unexpected inactivation of acceptor consensus splice sequence by a -3 C to T transition in intron 2 of the CFTR gene","volume":"94","author":"Bienvenu","year":"1994","journal-title":"Hum. Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/thx.2005.043539","article-title":"Cystic fibrosis: Terminology and diagnostic algorithms","volume":"61","author":"De Boeck","year":"2006","journal-title":"Thorax"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/hmg\/2.11.1965","article-title":"A donor splice mutation (405 + 1 G-->A) in cystic fibrosis associated with exon skipping in epithelial CFTR mRNA","volume":"2","author":"D\u00f6rk","year":"1993","journal-title":"Hum. Mol. Genet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1164\/rccm.201710-1983OC","article-title":"Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"197","author":"Graeber","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1164\/rccm.201507-1271LE","article-title":"Intestinal current measurements detect activation of mutant CFTR in patients with cystic fibrosis with the G551D mutation treated with ivacaftor","volume":"192","author":"Graeber","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e000736","DOI":"10.1136\/bmjresp-2020-000736","article-title":"Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test","volume":"7","author":"Minso","year":"2020","journal-title":"BMJ Open Respir. Res. 7"},{"key":"B13","unstructured":"S2-Konsensus-Leitlinie \u201eDiagnose der Mukoviszidose\u201d\n            N\u00e4hrlichL.\n            Stuhrmann-SpangenbergM.\n            BarbenJ.\n            BargonJ.\n            BlankensteinO.\n            BremernW.\n          10.5167\/uzh-919492013"},{"key":"B14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jcf.2021.10.005","article-title":"CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the \u03b2-adrenergic sweat rate assay","volume":"21","author":"Pallenberg","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B15","volume-title":"A language and environment for statistical computing","year":"2018"},{"key":"B16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-61779-117-8_6","article-title":"Nasal potential difference measurements to assess CFTR ion channel activity","volume":"741","author":"Rowe","year":"2011","journal-title":"Meth. Mol. Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1172\/JCI111385","article-title":"Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro","volume":"73","author":"Sato","year":"1984","journal-title":"J. Clin. Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1164\/rccm.201003-0382OC","article-title":"Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"00408","DOI":"10.1183\/23120541.00408-2020","article-title":"Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases","volume":"6","author":"Stahl","year":"2020","journal-title":"ERJ Open Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","article-title":"Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis","volume":"195","author":"Stahl","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: A 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jcf.2019.06.012","article-title":"Mild cystic fibrosis in carriers of two nonsense mutations \u2013 A case of genetic compensation response?","volume":"18","author":"T\u00fcmmler","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"B25","volume-title":"Mutation-specific therapies in cystic fibrosis","author":"T\u00fcmmler","year":"2022"},{"key":"B26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/BF02346181","article-title":"Geographic distribution and origin of CFTR mutations in Germany","volume":"97","author":"T\u00fcmmler","year":"1996","journal-title":"Hum. Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B28","first-page":"C34","volume-title":"Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline\u2014Thrid Edition","author":"Wayne","year":"2009"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1172\/JCI117172","article-title":"A novel exon in the cystic fibrosis transmembrane conductance regulator gene activated by the nonsense mutation E92X in airway epithelial cells of patients with cystic fibrosis","volume":"93","author":"Will","year":"1994","journal-title":"J. Clin. Invest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jcf.2022.02.001","article-title":"How the sweat gland reveals levels of CFTR activity","volume":"21","author":"Wine","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1152\/japplphysiol.00338.2021","article-title":"Correction of sensor crosstalk error in Exhalyzer D multiple-breath washout device significantly impacts outcomes in children with cystic fibrosis","volume":"131","author":"Wyler","year":"2021","journal-title":"J. Appl. Physiol. (1985)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A Phase 3 Open-Label Study of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1153656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T05:58:03Z","timestamp":1679896683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1153656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":32,"alternative-id":["10.3389\/fphar.2023.1153656"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1153656","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"article-number":"1153656"}}